Company intelligence / Profile preview
Revelar Biotherapeutics
Bethesda, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead antibody RBT-0813 for COVID-19 has demonstrated neutralization of all known SARS-CoV-2 variants of concern in preclinical studies. The company plans to enter clinical studies in 2022.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- AntibodiesBispecific antibodiesVHH single-domain antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Twist Bioscience
Beyond the preview
Go deeper on Revelar Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revelar Biotherapeutics.